SCHEMBL259557

SCHEMBL259557

COc1cc(-c2nc3ccc(O)cc3c(=O)[nH]2)cc(OC)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.57
CYP1B1 Q16678 2/20 0.57
CYP1A2 P05177 1/20 0.57
GUSB P08236 4/20 0.54
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
PDGFRB P09619 2/20 0.49
KIT P10721 2/20 0.49
KDR P35968 2/20 0.49
TNKS O95271 1/20 0.48
PARP1 P09874 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
CDK4 P11802 1/20 0.47
CCND1 P24385 1/20 0.47
CSNK2A2 P19784 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16017996 0.83 GUSB (0.76) CYP1A1CYP1B1CYP1A2GUSBKMT2A
SCHEMBL259429 0.82 TUBB4A (0.52) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL15689779 0.77 CYP1A1 (0.77) CYP1A1CYP1B1CYP1A2GUSBTNKS
SCHEMBL11099539 0.77 GUSB (0.64) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL13298758 0.77 TNKS (0.72) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL277488 0.75 TNKS (0.51) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL259526 0.75 TNKS (0.59) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL259542 0.74 KDM4E (0.56) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL259248 0.74 TNKS (0.58) CYP1A1CYP1B1CYP1A2GUSBKDM4E
SCHEMBL11379972 0.73 GUSB (0.68) CYP1A1CYP1B1CYP1A2GUSBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A CYP1A1 4306/4885CYP1B1 3472/4885CYP1A2 3921/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A CYP1A1 4306/4885CYP1B1 3472/4885CYP1A2 3921/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A CYP1A1 4306/4885CYP1B1 3472/4885CYP1A2 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.